跳至主要内容
临床试验/NCT01821300
NCT01821300已完成不适用

Cardiometabolic Risk and Obesity in Adolescents With Down Syndrome

Children's Hospital of Philadelphia2 个研究点 分布在 1 个国家目标入组 257 人开始时间: 2013年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
257
试验地点
2
主要终点
Non-HDL Cholesterol

研究概览

简要总结

The purpose of this research study is to determine which measures best capture cardiovascular disease (CVD) risk and type 2 diabetes (T2DM) risk in children and adolescents with Down syndrome (DS).

We hypothesize that DS is associated with worse cardiometabolic risk factors for a given body mass index compared to controls. This difference arises at least in part, from increased fat tissue.

详细描述

DS affects 1 per 800 births and is one of the most common causes of developmental disability in the US. Life expectancy for Down syndrome has increased significantly: estimated median survival in the US in 1997 was 49 years. DS is associated with an increased risk for obesity, with an estimated prevalence of 47-48% in adults and 30-50% in children with DS. Adolescents with DS are more likely to have increased adiposity compared to unaffected peers and may be at increased risk for obesity-related co-morbidities, such as type 2 diabetes and cardiovascular disease. How one defines obesity in DS is not clear. Individuals with DS have short stature and possibly increased adiposity, and the body mass index (BMI) used to define obesity for otherwise healthy populations may not accurately depict body fatness or capture cardiometabolic risk in DS.

Congenital heart disease (CHD) affects approximately 50% of individuals with DS; the National Institutes of Health Heart Lung and Blood Institute (NHLBI) Working Group on Obesity and Other Cardiovascular Risk Factors in Congenital Heart Disease highlighted the high prevalence of obesity in the setting of CHD, and called for studies to identify obesity measures that are more sensitive than BMI as well as studies of CVD risk prevention. Unfortunately, clinicians caring for obese adolescents with DS with or without CHD have little scientific evidence upon which to base guidance regarding cardiometabolic risk (CMR): data regarding CVD risk and prevalence of pre-diabetes and T2DM in obese adolescents with DS are lacking.

The measure of body fatness which best predicts CMR in DS is not known. We plan to compare BMI and other measures of body fatness in healthy controls and adolescents with DS to determine which measures best capture CVD and/or T2DM risk. These data will equip medical providers with the tools to better assess risk, initiate prevention measures, and guide screening in adolescents with DS.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
10 Years 至 20 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Both groups: Ages 10 - 20
  • Both groups: Parental/guardian permission (informed consent) and if appropriate, child assent.
  • Down syndrome group only: diagnosis of Down syndrome
  • Exclusion Criteria (both groups):
  • Major organ system illness (such as leukemia), except for type 2 Diabetes
  • Cyanotic congenital heart disease and/or pulmonary hypertension
  • Medically unstable congenital heart disease
  • Pregnancy
  • Genetic syndrome known to affect glucose tolerance
  • Familial hypercholesterolemia
  • Currently treated with medications known to affect insulin sensitivity (other than diabetes agents in participants with type 2 diabetes)

排除标准

  • 未提供

结局指标

主要结局

Non-HDL Cholesterol

时间窗: Study Visit 1

Non-HDL cholesterol measured via fasting blood draw

Lipid Subparticles

时间窗: Study Visit 1

Lipoprotein subclass particle analysis run on samples from fasting blood drawn Study Visit 1.

Body Mass Measures

时间窗: Study Visit 1

Adiposity measured by Dual-energy X-ray absorptiometry

Insulin Resistance

时间窗: Study Visit 1

Insulin Resistance (HOMA-IR) was calculated as \[fasting insulin (uIU/mL) x fasting glycemia (mmol/L)\]/22.5

Cardiometabolic Risk Biomarker Proteins

时间窗: Study Visit 1

hs-CRP, PAI-1, and IL-6 run on samples from fasting blood drawn Study Visit 1.

Abnormal Glucose Tolerance

时间窗: Study Visit 1

Impaired fasting glucose (IFG) was defined as fasting glucose ≥ 100 mg/dl. Impaired glucose tolerance (IGT) was defined as 2-hour glucose 140-199 mg/dl measured as part of an oral glucose tolerance test.

Visceral Fat

时间窗: Study Visit 1

Adiposity measured by Dual-energy X-ray absorptiometry

Left Ventricular Mass

时间窗: Study Visit 1

Cardiac end organ injury assessed by echocardiography. Left Ventricular Mass (LVM) was measured by area/length method using the apical four-chamber and parasternal short-axis views. LVM was calculated as LV area × LV length × 1.05 × 5/6.

Pulse Wave Velocity

时间窗: Study Visit 1

Cardiac end organ injury assessed by Pulse Wave Velocity (PWV)

Lipid Subparticles (Size)

时间窗: Study Visit 1

Lipoprotein subclass particle analysis run on samples from fasting blood drawn Study Visit 1.

次要结局

  • Health Related Quality of Life - PedsQL(Study Visit 1)
  • Health Related Quality of Life - IWQOL(Study Visit 1)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验